Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187321 | 1.00 | CA1 (0.34) | CA1CA2CA4KMT2ACYP3A4 | |
| SCHEMBL21563102 | 0.77 | — | — | |
| SCHEMBL1603148 | 0.76 | KDM4E (0.31) | KMT2A | |
| SCHEMBL231085 | 0.76 | — | — | |
| SCHEMBL19822417 | 0.76 | — | — | |
| SCHEMBL1603147 | 0.76 | KDM4E (0.31) | KMT2A | |
| SCHEMBL822975 | 0.76 | — | — | |
| SCHEMBL31756543 | 0.76 | — | — | |
| SCHEMBL12524744 | 0.76 | POLB (0.31) | — | |
| SCHEMBL12555452 | 0.76 | ALDH1A1 (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-8993547-B2 | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8642579-B2 | 1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8518917-B2 | 2-methylene-19-nor-vitamin D analogs and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120322775-A1 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120157418-A1 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110166170-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110082121-A1 | 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166170-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF | MDN1, VASP, ATRIP | CA1 900/4885CA2 437/4885CA4 3262/4885 |
| US-20110082121-A1 | 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | VDR, CYP24A1, CYP2R1 | CA1 4842/4885CA2 4786/4885CA4 4489/4885 |
| US-20120157418-A1 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | CYP24A1, CYP2R1, CYP27B1 | CA1 3872/4885CA2 3644/4885CA4 3132/4885 |
| US-20120322775-A1 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses | VDR, CYP24A1, CYP2R1 | CA1 4393/4885CA2 4100/4885CA4 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.